Titre : | Treatment costs of hepatitis C infection among injection drug users in Canada, 2006-2026 (2011) |
Auteurs : | D. WERB ; E. WOOD ; T. KERR ; N. HERSHFIELD ; R. W. H. PALMER ; R. S. REMIS |
Type de document : | Article : Périodique |
Dans : | International Journal of Drug Policy (Vol.22, n°1, January 2011) |
Article en page(s) : | 70-76 |
Langues: | Anglais |
Discipline : | MAL (Maladies infectieuses / Infectious diseases) |
Mots-clés : |
Thésaurus géographique CANADAThésaurus mots-clés HEPATITE ; TRAITEMENT ; COUT ; INJECTION ; MODELE ; INCIDENCE |
Résumé : |
Background Canadian injection drug users (IDUs) are at high risk of hepatitis C virus infection (HCV). However, little is known about the costs associated with their HCV-related medical treatment. We estimated the medical costs of treating HCV-infected IDUs from 2006 to 2026.
Methods We employed a Markov model of entry through birth or immigration to exposure-related behaviours or experiences, HCV infection, progression to HCV sequelae and mortality for active and ex-IDUs in Canada. We estimated direct and indirect treatment costs using data from the Ontario Case Costing Initiative (OCCI). Result Approximately 137,000 IDUs will suffer from HCV-related disease each year until 2026. Applying the OCCI cost data to the prevalence of HCV-related disease from 2006 to 2026 yielded an estimated cost of $3.96 billion CND to treat HCV-infected IDUs. Conclusions Substantial costs are associated with the treatment of HCV-related disease among Canadian IDUs. Given the lack of effective HCV prevention strategies in Canada, we must develop targeted evidence-based responses to prevent HCV transmission and ensure appropriate allocation of medical resources to meet the present and future treatment needs of HCV-infected IDUs. |
Domaine : | Drogues illicites / Illicit drugs |
Affiliation : | Dalla Lana School of Public Health, University of Toronto, 155 College Avenue, Room 512, Toronto, Ontario, Canada M5T 3M7 |
Accueil